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ABSTRACT
Objective To determine the rates of asymptomatic viral 
carriage and seroprevalence of SARS- CoV-2 antibodies in 
healthcare workers.
Design A cross- sectional study of asymptomatic 
healthcare workers undertaken on 24/25 April 2020.
Setting University Hospitals Birmingham NHS 
Foundation Trust (UHBFT), UK.
Participants 545 asymptomatic healthcare workers 
were recruited while at work. Participants were invited to 
participate via the UHBFT social media. Exclusion criteria 
included current symptoms consistent with COVID-19. 
No potential participants were excluded.
Intervention Participants volunteered a 
nasopharyngeal swab and a venous blood sample that 
were tested for SARS- CoV-2 RNA and anti- SARS- CoV-2 
spike glycoprotein antibodies, respectively. Results were 
interpreted in the context of prior illnesses and the 
hospital departments in which participants worked.
Main outcome measure Proportion of participants 
demonstrating infection and positive SARS- CoV-2 
serology.
Results The point prevalence of SARS- CoV-2 
viral carriage was 2.4% (n=13/545). The overall 
seroprevalence of SARS- CoV-2 antibodies was 
24.4% (n=126/516). Participants who reported prior 
symptomatic illness had higher seroprevalence (37.5% 
vs 17.1%, χ2=21.1034, p<0.0001) and quantitatively 
greater antibody responses than those who had 
remained asymptomatic. Seroprevalence was greatest 
among those working in housekeeping (34.5%), 
acute medicine (33.3%) and general internal medicine 
(30.3%), with lower rates observed in participants 
working in intensive care (14.8%). BAME (Black, Asian 
and minority ethnic) ethnicity was associated with a 
significantly increased risk of seropositivity (OR: 1.92, 
95% CI 1.14 to 3.23, p=0.01). Working on the intensive 
care unit was associated with a significantly lower risk of 
seropositivity compared with working in other areas of 
the hospital (OR: 0.28, 95% CI 0.09 to 0.78, p=0.02).
Conclusions and relevance We identify differences 
in the occupational risk of exposure to SARS- 
CoV-2 between hospital departments and confirm 
asymptomatic seroconversion occurs in healthcare 
workers. Further investigation of these observations 
is required to inform future infection control and 
occupational health practices.
INTRODUCTION
Healthcare workers are critical to the ongoing 
response to the SARS- CoV-2 pandemic. During the 
course of their work, they are exposed to hazards 
that place them at risk of infection.1 Previous 
studies have shown infection rates of up to 14% in 
symptomatic and 7.1% in asymptomatic healthcare 
workers,2 3 which are higher than general popula-
tion studies reported to date and suggest an occu-
pational risk.
Antibody responses have been demonstrated post 
infection with SARS- CoV-2, but it is not yet known 
whether these correlate with immunity, or how long 
antibody titres will be maintained. The magnitude 
of antibody responses appears proportional to age 
and severity of infection suffered.4 Asymptomatic 
seroconversion following exposure to SARS- CoV 
Key messages
What is the key question?
 ► What are the rates of asymptomatic viral 
carriage and the seroprevalence of SARS- CoV-2 
antibodies in UK healthcare workers?
What is the bottom line?
 ► In this study, the point prevalence of SARS- 
CoV-2 viral carriage was 2.4% and the overall 
seroprevalence of SARS- CoV-2 antibodies was 
24.4%.
Why read on?
 ► This study identifies differences in the risk of 
exposure of healthcare workers to SARS- CoV-2 
between ethnic groups and between hospital 
departments; these findings may inform future 
infection control and occupational health 
policy.
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and SARS- CoV-2 have been documented in small cohorts; again 
the quality and longevity of these immunological responses are 
unknown.1 5
Understanding the relationship between infection, symptom-
atology and the subsequent serological responses is critical to 
understanding herd immunity, vaccine deployment and safe-
guarding the workforce. Seroprevalence studies provide the 
foundation to inform this understanding.
University Hospitals Birmingham NHS Foundation Trust 
(UHBFT) is one of the largest hospital trusts in the UK with 
over 20 000 employees delivering care to 2.2 million people 
per annum. We conducted a cross- sectional study of 554 staff 
at UHBFT to determine the point prevalence of infection and 
seroprevalence of SARS- CoV-2 antibodies in healthcare workers 
and their relationship to prior symptoms of COVID-19 and the 
hospital departments in which participants worked.
METHODS
A cross- sectional study of asymptomatic healthcare workers at 
UHBFT was undertaken, recruiting 545 individuals who were 
at work over the course of 24 hours between 24 and 25 April 
2020. Initial invitation to participate in the study was made 
via social media. There was no predefined sample size; partic-
ipants self- reported for enrolment. Individuals were excluded if 
they reported symptoms of COVID-19 on the day. Individuals 
self- isolating at home due to personal symptomatic illnesses or 
illnesses in household contacts in the previous 2 weeks were 
indirectly excluded from the study.
All individuals volunteered a nasopharyngeal swab for 
SARS- CoV-2 RNA detection and a venous blood sample for 
anti- SARS- CoV-2 spike glycoprotein serology, tested using an 
ELISA developed inhouse by the University of Birmingham Clin-
ical Immunology Service. Detection of SARS- CoV-2 RNA was 
performed using real- time PCR (Viasure, CerTest Biotec) directed 
against the ORF1ab and N genes following guanidine isothiocy-
anate inactivation of nasopharyngeal swabs.6 Serological analysis 
was performed using a high- sensitivity ELISA developed inhouse 
by the University of Birmingham Clinical Immunology Service. 
Serological analysis was performed at biological containment 
level 2. High- binding plates (Greiner Bio- One) were coated with 
trimeric SARS- CoV-2 spike glycoprotein7 8 and blocked with 
StabilCoat solution (Sigma- Aldrich). Serum was prediluted 1:40 
prior to analysis. A combined secondary layer containing horse- 
radish peroxidase conjugated ovine polyclonal antibodies against 
IgG, IgA and IgM followed by 3,3′,5,5′-tetramethylbenzidine 
development was used to detect the presence of antibodies. The 
cut- off for positivity on the ELISA was set at 2 SD above the 
mean OD450 of eight pre-2019 negative sera run independently 
across seven separate plates.
Prior validation of this assay has shown it demonstrates 100% 
sensitivity in individuals with PCR- proven disease 7 days post 
symptom onset (n=59 hospitalised, n=31 community) and 
97.8% specificity based on 270 individual negative pre-2019 
samples. Intra- assay coefficient of variation (CV%) is 1.58% and 
interassay CV% is 7.5% for negative controls and 17.3% for 
positive controls and 7.2% for controls running at the cut- off of 
positivity on the assay.
Participants were asked to retrospectively report any illnesses 
consistent with COVID-19 that they had suffered in the previous 
4 months. Ethnodemographic data and their department of work 
were also recorded. UHBFT patient mortality data were sourced 
from NHS England and information on the total number of 
PCR- positive inpatients from the UHBFT infection control 
team. Indices of deprivation in participants’ postcodes were 
sourced from 2019 UK Ministry of Housing, Communities and 
Local Government statistics.9
Data were analysed using Graph Pad Prism V.8.4.2. Categor-
ical data were compared using the χ2 test and optical density 
distributions using the Kruskal- Wallis test with Dunn’s post- test 
comparison for symptomatic and asymptomatic groups. Sero-
prevalence data are expressed as a percentage, with binomial CI 
calculated using Wilson’s method. Indices of deprivation were 
transformed using the function [log(R)/(32 844−R)], where R 
represented the individual rank of a participant’s postcode within 
the national data; these parameters were specified as depriva-
tion scores; numerically lower values represent more deprived 
postcodes. Unpaired, two- tailed t- tests were used to compare the 
means of the seropositive and seronegative populations of these 
data. Using intensive care as a reference population, the rela-
tive risk (RR) of seropositivity for individuals working in other 
specific departments was determined, and the 95% CI for this 
RR was determined using Koopman’s asymptotic score method.
Univariate analysis and multiple logistic regression were 
performed using seropositivity as the outcome variable. Age, sex, 
ethnicity, Index of Multiple Deprivation score and the depart-
ments in which individuals worked were included as indepen-
dent variables. In univariate analysis, categorical variables were 
compared using two- sided χ2 tests, and OR was calculated using 
the Baptista- Pike method. In this analysis, the OR represents 
the odds of seropositivity for an individual working in that 
department compared with not working in that department. In 
multiple logistic regression involving continuous variables, the 
OR represents change in odds of seropositivity changes per each 
increasing year of age or increasing unit of deprivation score.
All participants provided written, informed consent prior to 
enrolment in the study.
RESULTS
The point prevalence of PCR positivity in asymptomatic health-
care workers was 2.4% (n=13/545). Of these individuals, 15.4% 
(n=2/13) had detectable anti- SARS- CoV-2 antibodies in their 
serum and 38.4% (n=5/13) subsequently became unwell with 
symptoms consistent with COVID-19. Serum was available 
for analysis on 516 individuals, and 26.3% (n=136/516) of 
participants reported a prior illness consistent with COVID-19 
(table 1). The overall seroprevalence across the cohort was 
24.4% (n=126/516); individuals reporting a prior symptomatic 
illness had significantly greater seroprevalence than those who 
had remained asymptomatic throughout the time period assessed 
(36.8% vs 17.1%, χ2=19.75, p<0.0001) (figure 1A). Antibody 
responses in individuals who had experienced a prior symptom-
atic illness were quantitatively greater than those who remained 
asymptomatic (Kruskal- Wallis statistics 7.159, p=0.02, Dunn’s 
post- test comparison of symptomatic vs asymptomatic individ-
uals: mean rank difference 17.02, adjusted p=0.02) (figure 1B).
We explored the relationship between the timing of health-
care worker illness associated with seropositivity and weekly 
trust- wide COVID-19 mortality, as a surrogate of overall patient 
burden (figure 1C). Illnesses associated with positive serology 
were occurring for over 3 weeks prior to UK lockdown. The 
temporal pattern of reported symptomatic illnesses associated 
with seropositivity in healthcare workers preceded that of trust- 
wide deaths by approximately 1 week. The highest incidence 
of symptomatic illness associated with seropositivity (77.8%, 
n=14/18) was observed in the week beginning 28 March 2020, 
1 week before peak weekly mortality was reached within UHBFT.
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Seroprevalence was mapped to the departments where indi-
viduals work within UHBFT (figure 1D). Seroprevalence was 
highest in those working in housekeeping (34.5%, n=10/29), 
acute medicine (33.3%, n=10/30) and general internal medi-
cine (30.3%, n=30/99) and lowest in participants working in 
intensive care (14.8%, n=9/61), emergency medicine (13.3%, 
n=2/15) and general surgery (13.0%, n=3/23). Using intensive 
care as a reference population, an increased RR of seropositivity 
was observed for those working in housekeeping (RR 2.34, CI 
1.07 to 5.01, p=0.03), acute medicine (RR 2.25, CI 1.04 to 
4.86, p=0.04) and general internal medicine (RR 2.05, CI 1.08 
to 4.05, p=0.03).
Univariate and multivariate analyses were undertaken using 
serostatus as the dependent variable and incorporating partic-
ipant age, sex, ethnicity, Index of Multiple Deprivation score 
of participants’ postcodes and the hospital departments where 
participants worked as independent variables (table 2). Women 
had a higher seroprevalence than men (26.3% vs 18.8%), but 
this difference was not statistically significant in univariate or 
multivariate analysis (adjusted OR: 1.49, 95% CI 0.81 to 2.83, 
p=0.07). Univariate and multivariate analyses both demon-
strated individuals of BAME (Black, Asian and minority ethnic) 
ethnicity were at significantly greater risk of seropositivity than 
individuals of white ethnicity (adjusted OR: 1.92, 95% CI 1.14 
to 3.23, p=0.01). Working in intensive care medicine was associ-
ated with significantly reduced risk of seropositivity in multivar-
iate analysis (adjusted OR: 0.28, 95% CI 0.09 to 0.78, p=0.02).
On average, the Index of Multiple Deprivation score was 
significantly lower in the home postcodes of BAME participants 
compared with white participants (−0.570 vs −0.232, t=3.747, 
p=0.0002). However, no significant differences between any 
individual government indices of deprivation were observed 
between individuals who were seropositive and seronegative in 
this study (table 3). Furthermore, in multiple logistic regression 
analysis, the Index of Multiple Deprivation did not influence 
serostatus in this study (OR 0.99, 95% CI 0.7387 to 1.323, 
p=0.9503). This supports an interpretation that the observed 
difference in seroprevalence rates in this cohort is more likely 
due to occupational risk, rather than external factors.
DISCUSSION
In this cross- sectional study of asymptomatic healthcare 
workers, the point prevalence of SARS- CoV-2 nasopharyngeal 
carriage (2.4%) was concordant with a contemporaneous UK 
study2 but less than an earlier study performed during the peak 
of the pandemic (cumulative total 14.0%).3 The relatively low 
prevalence of viral RNA carriage in our cohort appears to be 
in keeping with the national epidemiology of the first wave of 
the UK SARS- CoV-2 epidemic. In contrast, we report a higher 
overall SARS- CoV-2 seroprevalence of 24.4%. This suggests the 
cumulative infection rate determined using molecular testing 
should have been far higher than was reported in previous 
studies.2 3 This is consistent with data demonstrating the rela-
tive insensitivity of nasopharyngeal swabs in determining viral 
carriage,5 10 but may also reflect access to testing. With respect 
to the assay used to determine seropositivity, the coefficient of 
variance of internal quality control material designed to run 
close to the clinical cut- off of the assay was 7.2%, suggesting 
that true seroprevalence lies between 23.8% and 26.0% based 
on the data from our cohort. Thus, the overall seroprevalence 
of SARS- CoV-2 antibodies in healthcare workers in this study is 
significantly greater than the 6% seroprevalence in the general 
population of the Midlands region determined by Public Health 
Table 1 Demographics of study participants
All participants, n (%) Seropositive, n (%) Seronegative, n (%) Seroprevalence (%) P value
n 516 126 390 24.4
Age (years) 42 (30–51) 41 (30–51) 42 (31–51) 0.48
Sex
  Male 128 (24.8) 24 (19.0) 104 (26.7) 18.8 0.09*
  Female 388 (75.2) 102 (81.0) 286 (73.3) 26.3
Ethnicity
  Asian British Bangladeshi 2 (0.4) 2 (1.6) 0 (0.0) 100.0 0.18†
  Asian British Indian 25 (4.8) 6 (4.8) 19 (4.9) 24.0
  Asian British other/not stated 18 (3.5) 3 (2.4) 15 (3.8) 16.7
  Asian British Pakistani 11 (2.1) 4 (3.2) 7 (1.8) 36.4
  Black African 10 (1.9) 5 (4.0) 5 (1.3) 50.0
  Black British 17 (3.3) 5 (4.0) 12 (3.1) 29.4
  Filipino 21 (4.1) 6 (4.8) 15 (3.8) 28.6
  Mixed heritage 10 (1.9) 4 (3.2) 6 (1.5) 40.0
  Not disclosed 74 (14.3) 15 (11.9) 59 (15.1) 20.3
  Other 13 (2.5) 5 (4.0) 8 (2.1) 38.5
  White Irish 5 (1.0) 1 (0.8) 4 (1.0) 20.0
  White other 25 (4.8) 4 (3.2) 21 (5.4) 16.0
  White British 285 (55.2) 66 (52.3) 219 (56.2) 23.2
P values pertain to analysis of differences between seropositive and seronegative groups.
Median and IQR are provided.
*χ2=16.25, df=12.
†χ2=2.964, df=1, Z=1.722.
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England.11 Data from two other studies also found elevated 
infection or seroprevalence in healthcare workers compared with 
the general population.12 13 Collectively, these studies suggest a 
marked occupational risk of exposure to SARS- CoV-2 associated 
with healthcare work during the COVID-19 pandemic.
We identify variation in the seroprevalence of SARS- CoV-2 
antibodies among different groups of healthcare workers. The 
highest seroprevalence was observed in housekeepers (34.5%) 
and those working in acute medicine (33%) or general internal 
medicine (30.3%), with lower seroprevalence among partic-
ipants working in intensive care medicine (14.8%). Multiple 
logistic regression confirmed a significantly lower risk of sero-
positivity in individuals working in intensive care medicine. 
This strongly supports the conclusion that differential risk of 
SARS- CoV-2 exposure exists within the hospital environment. 
The reasons underlying this are likely to be multifactorial: in 
accordance with national guidelines, intensive care units were 
designated high- risk environments and the use of enhanced 
personal protective equipment (PPE) including filtered face 
piece (class 3) respirators mandated. In contrast, fluid- resistant 
surgical masks were recommended in other clinical areas. The 
contribution of enhanced PPE in protecting staff from infection 
with SARS- CoV-2 should be studied further, including the avail-
ability of training, space and supervision to use PPE effectively. 
Differential occupational exposure to severe respiratory viruses 
was previously observed during the 2003 SARS- CoV outbreak.14
We demonstrate that BAME ethnicity confers a significantly 
increased risk of seropositivity in this study. Although individuals 
of BAME ethnicity within this study, on average, lived in signifi-
cantly more deprived areas, the Index of Multiple Deprivation 
score of participants’ home postcode did not significantly influ-
ence serostatus within our multiple logistic regression model. It 
is not clear from our study whether this increased risk of sero-
positivity arises from a greater risk of exposure to the virus, or 
a greater risk of infection if exposed to the SARS- CoV-2 virus. 
Regardless of the cause, this finding demands urgent further 
investigation, particularly in view of the ethnic disparities in the 
outcome from COVID-19.15
We demonstrate viral carriage in 2.4% of asymptomatic 
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29 30 99 37 28 57 47 37 18 61 15 23Total (n)
Seropositive (n) 10 10 30 11 8 9 7 3 9 2 3
Figure 1 (A) Seroprevalence rates in study participants self- reporting prior symptomatic illnesses consistent with COVID-19 compared with 
asymptomatic individuals. (B) Optical density (OD) of anti- SARS- CoV-2 antibodies in individuals with positive serology classified by self- reported 
prior symptomatic illness (n=126). Line shows the median value of each group. (C) Timing of prior symptomatic illness in study participants and their 
relationship with seroprevalence of SARS- CoV-2 antibodies, total inpatients at UHBFT who had tested positive for SARS- CoV-2 by PCR and overall 
UHBFT- wide deaths in the weeks of March and April 2020. (D) Seroprevalence of SARS- CoV-2 antibody in study participants by department in which 
they work. AMU, acute medical unit; ED, emergency department; ITU, intensive care unit; OBGYN, obstetrics and gynaecology; OPD, outpatient 
department; R&D, research and development; UHBFT, University Hospitals Birmingham NHS Foundation Trust.
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of prior symptomatology in 17.1%. Using similar immunolog-
ical methods, Hains et al5 reported seroconversion in 44.0% 
(n=11/25) of healthcare workers in a US dialysis unit, including 
asymptomatic seroconversion. It is not known whether asymp-
tomatic viral carriage leads to transmission in the hospital setting 
and it is not possible to interrogate this retrospectively. However, 
our data would support the assessment of widespread healthcare 
worker testing, including track and trace, on viral transmission 
during future waves of a pandemic.16
Finally, in keeping with previous studies that have correlated 
the severity of COVID-19 with the magnitude of the consequent 
antibody response,4 we demonstrate that antibody responses 
were, on average, significantly greater in individuals with 
prior symptomatic illness compared with those who remained 
asymptomatic. Further studies must determine the neutralising 
capacity of antibody responses associated with different severi-
ties of disease, the titres at which neutralising antibodies provide 
protection against infection and the duration of that protection.
There are a number of limitations to our cross- sectional study. 
Participants self- presented to enrol, which may introduce bias in 
the study cohort; however, the balance of participants working 
in intensive care, acute medicine and general internal medicine 
represents a fair reflection of front- line staff caring for patients 
with COVID-19. Both acute and non- acute, non- patient- facing 
occupational groups were recruited to enable comparison. 
Data were not available to determine how representative our 
sampling was through comparison of the numbers recruited to 
individual groups with the total number of staff at work on the 
day of the study. By failing to capture more recent infections 
leading to seroconversion, this may underestimate the true sero-
prevalence, although this study would have captured the peak 
of the pandemic. The relationship between symptomatic illness 
and antibody positivity requires confirmation in larger studies, 
particularly given that 19.2% (n=99/516) of participants did 
not provide information about whether they had suffered a 
prior symptomatic illness before serological analysis was under-
taken. Further studies are necessary to consider whether the 
increased risk of seropositivity observed within individuals of 
BAME ethnicity is homogeneous throughout the individual 
ethnic populations that collectively constitute the BAME group. 
Finally, longitudinal studies will be required to demonstrate the 
persistence of current seropositivity and to directly attribute 
seroconversion events to PCR- proven SARS- CoV-2 infection.
In conclusion, we document the high seroprevalence of 
SARS- CoV-2 antibodies in healthcare workers with and without 
prior symptomatic illness and identify the groups of workers 
who have significantly different seroprevalence, suggesting 
differential occupational risk.
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Table 2 Multiple logistic regression model incorporating seropositivity at time of study as the dependent variable and age, sex, ethnicity, Index of 
Multiple Deprivation score and department in which participants worked at the time of the study as independent variables
Variable Unadjusted OR 95% CI P value Z Adjusted OR 95% CI Z P value
Age – – – 0.98 0.96 to 1.00 0.60 0.55
Sex (female) 1.54 0.94 to 2.56 0.09 1.72 1.49 0.81 to 2.83 1.79 0.07
Ethnicity (BAME) 1.58 1.01 to 2.49 0.05 1.97 1.92 1.14 to 3.23 1.26 0.01
Index of Multiple Deprivation score – – – 0.99 0.74 to 1.32 2.46 0.95
Acute medicine 1.60 0.76 to 3.37 0.24 1.17 0.99 0.34 to 2.86 0.01 0.99
Emergency department 0.47 0.10 to 1.81 0.31 1.01 0.36 0.05 to 1.69 1.19 0.23
Estates 0.61 0.18 to 2.00 0.43 0.78 0.57 0.11 to 2.29 0.75 0.45
General internal medicine 1.45 0.89 to 2.32 0.13 1.52 0.93 0.42 to 2.12 0.17 0.86
General surgery 0.45 0.14 to 1.37 0.19 1.30 0.24 0.03 to 1.05 1.71 0.09
Facilities 0.71 0.29 to 1.63 0.41 0.81 0.52 0.15 to 1.60 1.10 0.45
Housekeeping 1.68 0.79 to 3.62 0.19 1.30 1.01 0.31 to 3.09 0.02 0.99
Intensive care 0.50 0.24 to 1.01 0.06 1.87 0.28 0.09 to 0.78 2.37 0.02
Obstetrics and gynaecology 1.34 0.63 to 2.71 0.44 0.78 0.85 0.30 to 2.39 0.30 0.77
Research and development 0.71 0.33 to 1.50 0.38 0.88 0.44 0.15 to 1.22 1.54 0.12
Unadjusted OR and adjusted OR following multiple logistic regression are presented. OR presented for individual hospital departments represents the odds of seropositivity for 
individuals working in that department compared with not working in that department. Statistically significant OR are in bold (p<0.05)
The area under the receiver operating characteristic curve of this model was 0.675 (95% CI 0.619 to 0.732, p<0.0001).
BAME, Black, Asian and minority ethnic.
Table 3 Indices of deprivation scores associated with home postcode 
of study participants
Index of deprivation Seropositive Seronegative P value
Index of Multiple Deprivation −0.395 (0.89) −0.345 (0.79) 0.58
Income −0.352 (0.99) −0.316 (0.80) 0.69
Employment −0.267 (1.00) −0.312 (0.78) 0.61
Education and skills −0.149 (0.87) −0.160 (0.76) 0.90
Health and disability −0.361 (0.73) −0.347 (0.60) 0.84
Barriers to housing and services −0.446 (0.57) −0.333 (0.60) 0.07
Living environment −0.433 (0.78) −0.444 (0.71) 0.88
Income deprivation affecting children −0.381 (0.93) −0.333 (0.80) 0.59
Income deprivation affecting older adults −0.369 (0.88) −0.274 (0.75) 0.25
Mean and SD (in parentheses) are provided. Numerically lower values represent more 
deprived postcodes.
Means of seropositive and seronegative groups were compared using the unpaired, two- 
tailed Student’s t- test.
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